Abstract In the United States, two patients with the same medical condition can receive
drastically different treatments. In addition, the same patient can walk into two physicians' …

Purpose: The epidemiology and treatment of prostate cancer have changed dramatically in
the prostate specific antigen era. A large disease registry facilitates the longitudinal …

Background Robust data on patient-reported outcome measures comparing treatments for
clinically localized prostate cancer are lacking. We investigated the effects of active …

Purpose SpaceOAR, a Food and Drug Administration–approved hydrogel intended to create
a rectal–prostate space, was evaluated in a single-blind phase III trial of image guided …

This first-in-man imaging study evaluated the safety and feasibility of hyperpolarized [1-13C]
pyruvate as an agent for noninvasively characterizing alterations in tumor metabolism for …

Background We sought to identify determinants of health-related quality of life after primary
treatment of prostate cancer and to measure the effects of such determinants on satisfaction …

Purpose In the absence of high-level evidence or clinical guidelines supporting any given
active treatment approach over another for localized prostate cancer, clinician and patient …

Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among
patients with localized prostate cancer. We devised a novel risk assessment tool which …

Purpose Prostate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate
cancer is widely used for reporting the outcome of radical prostatectomy (RP). A …

Background: Men treated for clinically localized prostate cancer with either radical
prostatectomy or external beam radiotherapy usually survive many years with the side …